Enzalutamide

Drug Profile

Enzalutamide

Alternative Names: ASP 9785; MDV 3100; Xtandi

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator University of California at Los Angeles; University of Texas M. D. Anderson Cancer Center
  • Developer Astellas Pharma; H. Lee Moffitt Cancer Center and Research Institute; M. D. Anderson Cancer Center; Medivation; National Cancer Institute (USA); Queen Mary University of London; The Prostate Cancer Clinical Trials Consortium; University of California, Davis; University of Chicago
  • Class Antineoplastics; Benzamides; Fluorobenzenes; Imidazolidines; Nitriles; Small molecules; Thiones
  • Mechanism of Action Androgen receptor antagonists; Apoprotein stimulants; Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase III Breast cancer
  • Phase II Endometrial cancer; Hepatocellular carcinoma; Salivary gland cancer
  • Phase I Pancreatic cancer

Most Recent Events

  • 06 Dec 2016 Positive interim efficacy and adverse events data from a phase II trial in Breast cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) presented at the 39th Annual San Antonio Breast Cancer Symposium (SABCS-2016)
  • 14 Nov 2016 Expanded access phase II trial for Prostate cancer is no longer available in Australia, Belgium, Canada, Chile, Czech Republic, Denmark, France, Georgia, Germany, Moldova, Netherlands, Russia, South Africa, Spain, United Kingdom, USA as the treatment is approved for sale to the public (PO, Capsule) (EudraCT2016-001694-32; NCT02960022)
  • 01 Nov 2016 Astellas Pharma Global Development initiates an expanded access phase II trial for Prostate cancer in Australia, Belgium, Canada, Chile, Czech Republic, Denmark, France, Georgia, Germany, Moldova, Netherlands, Russia, South Africa, Spain, United Kingdom, USA (PO, Capsule) (EudraCT2016-001694-32; NCT02960022)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top